Oral lactoferrin in the treatment of respiratory disorders
The present invention relates to methods of treating an allergic or non-allergic respiratory disorder by administering orally a composition of lactoferrin alone or in combination with metal chelators to treat respiratory disorders.
1. A method of treating having asthma comprising the step or steps of administering orally to a subject a lactoferrin composition in an amount sufficient to provide an improvement in the asthma in said subject and administering a metal chelator dispersed in a pharmaceutically acceptable carrier in an amount sufficient to enhance the efficacy of the lactoferrin in the lactoferrin composition for treating asthma.
2. The method of claim 1 , wherein said lactoferrin composition is dispersed in a pharmaceutically acceptable carrier.
3. The method of claim 1 , wherein said lactofenin is mammalian lactoferrin.
4. The method of claim 3 , wherein said lactoferrin is human or bovine lactofenin.
5. The method of claim 1 , wherein said lactofenin is recombinant lactoferrin.
6. The method of claim 1 further comprising administering an antacid in conjunction with said lactoferrin composition.
7. The method of claim 1 , wherein the amount of the lactoferrin in the composition that is administered is about 1 mg to about 10 g per day.
8. The method of claim 1 , wherein the amount of the lactoferrin in the composition that is administered is about 10 mg to about 1 g per day.
9. The method of claim 1 , wherein the asthma is selected from the group consisting of atopic asthma-and non-atopic asthma.
10. The method of claim 1 , wherein the metal chelator is ethylenediaminetetraacetic acid (EDTA), [ethylenebis (oxyethylenenitrilo)] tetraacetic acid (EGTA), 1,2-bis(2-aminophenoxy)eth-ane-N,N,N′,N′-tetraacetic acid (BAPTA), or hydroxyethlene triamine diacetic acid, (HEDTA).
11. The method of claim 10 , wherein the metal chelator is EDTA.
12. The method of claim 11 , wherein the amount of EDTA that is administered is about 0.01 μg to about 20 g per day.
13. The method of claim 11 , wherein the ratio of EDTA to lactofenin in the composition that is administered is from 1:10,000 to about 2:1.
14. The method of claim 1 further comprising administering an anti-asthma therapy selected from the group consisting of mast cell degranulation agents, leukotriene inhibitors, corticosteroids, beta-antagonists, IgE binding inhibitors, anti-CD23 antibody, tryptase inhibitors, and VIP agonists and combinations thereof.